About Philippa

Professor Philippa Easterbrook is Senior Scientist in the Global Hepatitis Programme, HIV department at the World Health Organisation Headquarters in Geneva. For the last five years, she has led and coordinated the scientific research and programmatic vision in the development and dissemination of global normative guidance first on the use of antiretroviral therapy in adult, pregnant women and children; diagnosis and management of cryptococcal infection – a major cause of mortality in HIV-infection; and more recently on the care and treatment of hepatitis B and C infection and just launched hepatitis testing in low and middle-income countries. She also provides technical leadership and guidance to country Ministries of Health on the implementation of hepatitis testing and treatment scale-up and access programmes to lower cost diagnostics and drugs worldwide. She serves as vice-chair of the WHO Guidelines Review Committee.

She graduated with first class honours in Biochemistry from University of London and then Distinction in Medicine from University of Cambridge, and completed her training in general medicine and infectious diseases in London, Oxford and Birmingham. As a Harkness fellow at Johns Hopkins University in the United States, she trained in public health and epidemiology, and was subsequently Senior Lecturer in Infectious Diseases and Epidemiology at Imperial College. For eleven years, she was Head of Department, Professor of HIV Medicine, and consultant physician in Infectious Diseases at King´s College London, and also served as Head of Research at the Infectious Diseases Institute, Makerere University, Kampala during a sabbatical. At the University of KwaZulu Natal, South Africa, she led a province-wide three year technical assistance and training programme for the rapid expansion of antiretroviral programmes in KwaZulu-Natal, supported by US Presidents Emergency Fund for AIDS Relief (PEPFAR). Her research programme has encompassed epidemiology, clinical trials, operational and qualitative research, as well as collaborative laboratory based studies on the mechanisms of resistance to HIV and “non-progression”. She has published more than 250 peer-reviewed articles, and three books, including a best seller “Basic Medical Sciences for MRCP”.

This speaker will be presenting at the following session(s)

  • Testing interventions

    Ballroom 1

    Day: 2 November

    Time: 14:00

    Chairs: Dr. Maria Cassia Mendes-Correa, Sao Paulo University, Brazil and Dr. Francesco Negro Geneva University Hospital, Switzerland

    Presentations:

    • Introduction including a brief overview of WHO testing guidelines and implementation.
    • Prof. Philippa Easterbrook, World Health Organization
    • Diagnostics: present and future innovations.
    • Dr. Saleem Kamili, US Centers for Disease Control and Prevention
    • Are HBV community-based screening campaigns feasible and acceptable: the PROLIFICA experience.
    • Dr. Maud Lemoine, Imperial College London, UK
    • Scaling-up a national screening programme for hepatitis C.
    • Dr. Radi Hammad, Ministry of Health, Egypt
    • Q & A session.

    Session objectives:

    • Review the scientific, logistical, ethical and political process leading to the implementation of state-of-the-art testing for viral hepatitis.
    • Discuss the feasibility and validity of diagnostic algorithm simplifications.
    • Define what testing strategies should be applied in different settings.
    • Discuss the preliminary results of testing strategies in selected areas.
  • Hepatitis in children

    Chagal

    Day: 2 November

    Time: 18:00

    This evening side meeting looks at hepatitis in children and adolescence. The session will explore some of the recent advances in pediatrics as well as the unique challenges that still need to be overcome within this area.

    Presentations:

    • Global overview of hepatitis in children: WHO perspective.
      Prof. Philippa Easterbook, World Health Organization
    • Towards elimination of HBV in Children: prevention perspective.
    • Towards elimination of HCV in children: clinical and treatment perspective.
      Prof. Manal El-Sayed, Ain Shams University, Egypt
    • Panel discussion.
      Prof Saeed Hamid (Pakistan), Prof Funmi Lesi (Nigeria), Prof Gilda Porta (Brazil)
  • End of viral hepatitis? Not without tackling hepatitis E!

    Chagal

    Day: 2 November

    Time: 07:30

    This early morning side meeting will look at this neglected form of the hepatitis virus and the limited strategies to control it. With no efficacious treatment available for acute fulminant hepatitis E and a limited impact from improvements in water and sanitation in displaced populations, this meeting will examine what can be done to limit the burden worldwide. 

    Presentations:

    • Introduction: Hepatitis E in humanitarian settings.
      Iza Ciglenecki,‎ Médecins Sans Frontières
    • Hepatitis E in developing countries: an old disease?
      Dr. Rakesh Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences
    • Hepatitis E in developed countries: a new disease?
      Dr. Harry Dalton, Royal Cornwall Hospitals NHS Trust
    • Hepatitis E vaccine: a new control tool?
      Dr. James Shih, Innovax
    • Round table discussion.
      Moderator: Dr. Harry Dalton, Royal Cornwall Hospitals NHS Trust
      with Dr Rajendra Pant, Dr Rakesh Aggarwall, Dr Philippa Easterbrook